High-Quality STROMUSC LGD4033 10mg For Bodybuilding CAS:1165910-22-4

   What Is LGD4033?

    LGD4033-known colloquially as Ligandrol, and sometimes referred to by its research codes VK5211 or Anabolicum-belongs to a class of compounds called selective androgen receptor modulators, or SARMs. Unlike traditional anabolic steroids that flood the entire body with androgenic activity, SARMs were engineered to bind androgen receptors selectively in specific tissues. LGD4033 in particular binds the androgen receptor with exceptionally high affinity-a Ki of approximately 1 nanomolar-and does so preferentially in skeletal muscle and bone tissue.

    The pharmacological premise is elegant in its simplicity: drive the same anabolic signaling pathways that testosterone activates-IGF-1, MyoD, myogenin, and the downstream machinery of myofibrillar protein synthesis-while largely sparing the prostate, sebaceous glands, and scalp from androgenic stimulation. In muscle and bone, LGD4033 acts as a full agonist. In prostate and skin tissue, it recruits a different set of cofactors and behaves as only a weak partial agonist. This tissue selectivity is the entire reason the compound was developed in the first place-a non-steroidal, orally bioavailable molecule that could treat muscle-wasting conditions like sarcopenia, muscular dystrophy, and cancer cachexia without the baggage of traditional androgen therapy.

    The original Phase 1 clinical trial, published in the Journals of Gerontology in 2013, demonstrated that even at doses as low as 0.1 mg per day, LGD4033 produced measurable increases in lean body mass over just 21 days. Importantly, the study found no significant changes in prostate-specific antigen, suggesting the compound was indeed sparing the prostate as intended. Higher doses in that trial produced greater lean mass accrual but also more pronounced suppression of endogenous testosterone-a trade-off that would define the compound's risk-reward profile.

    It is critical to understand that LGD4033 has never been approved by the FDA, the TGA, or any major regulatory body for human use. It remains a research chemical, and its use in bodybuilding exists entirely outside the framework of legitimate medical practice.

    A properly manufactured 10mg LGD4033 tablet should deliver several defining characteristics. The compound itself is a non-steroidal small molecule with a molecular weight of approximately 338.24 g/mol. Its oral bioavailability is reported to be around 90 percent, meaning that very little of the active compound is lost to first-pass metabolism. This high bioavailability is one of the reasons LGD4033 has become so popular in the bodybuilding community-what you take orally is almost entirely absorbed and available to bind androgen receptors.

    Time to peak plasma concentration is roughly two hours after oral administration. The compound exhibits linear pharmacokinetics with dose-proportional accumulation upon multiple dosing. In plain terms, this means that doubling the dose roughly doubles the drug concentration in the blood, and daily administration leads to predictable, steady accumulation rather than unexpected spikes. This predictability makes dosing relatively straightforward compared to compounds with more erratic pharmacokinetic profiles.

    The elimination half-life of LGD4033 is consistently reported in the literature as 24 to 36 hours. This extended half-life supports once-daily oral dosing, as the compound maintains appreciable plasma levels throughout a 24-hour period. In fact, sustained systemic exposure has been observed with detectable plasma levels still present a full week after the final dose. This long tail has important implications for both cycle design and post-cycle therapy timing.

    A top-quality tablet should also be manufactured with consistent dosing, proper excipients for stability, and storage stability at room temperature in a dry environment away from light. The research-grade standard calls for 10mg per tablet with minimal batch-to-batch variation-a standard that is unfortunately not guaranteed in the largely unregulated SARM marketplace.

    LGD4033 has carved out a specific niche in the bodybuilding world. It is primarily sought after for bulking phases, where the goal is maximal lean tissue accretion. Users consistently report that LGD4033 delivers "AAS-adjacent" lean mass gains without the need for injections, without the risk of estrogenic side effects from aromatization, and without the severe androgenic sides associated with compounds like testosterone or Dianabol.

    The compound is particularly valued for its predictability. Unlike RAD140, which can produce dramatic but sometimes unpredictable results with harsher sides, LGD4033 offers steady, reliable lean mass gains. One user who ran a 10mg cycle for 10 weeks reported gaining enough mass that shirts went from an XL to a 2XL, with people openly commenting on the visible size increase. Another user on a six-week cycle of LGD4033 stacked with MK677 gained 8 to 12 pounds. These anecdotal reports align with the clinical data showing dose-dependent increases in lean body mass.

    The compound also finds application in recomposition and even cutting phases, though its primary strength remains mass building. Users report improved recovery between training sessions, greater muscle fullness, and a noticeable increase in strength that typically begins manifesting within the first two weeks of a cycle. One user described the experience as "strength went up and stayed up, muscle size was gained and kept".

    However, it is worth noting that LGD4033 does cause some water retention-mild to moderate, and not estrogen-mediated, but enough that users often describe a "puffier" look, particularly in the midsection and face. This water weight contributes to the scale weight increase but is not the same as the gynecomastia-inducing water retention caused by aromatizing compounds.

    The benefits of LGD4033 are both clinically documented and anecdotally validated. Clinical trials have shown that LGD4033 significantly increases lean body mass in healthy young men, with even the lowest tested doses producing measurable effects. A 2018 trial examining LGD4033 in elderly patients recovering from hip fractures found that those taking the compound significantly increased their muscle mass and could walk further than patients not on the drug.

    For the bodybuilder, the practical benefits translate to:

    Lean Mass Accrual: The compound delivers 4 to 8 pounds of lean tissue in a trained individual over a standard 8-week cycle at 5 to 10mg per day. This is substantial enough to produce visibly noticeable changes in physique.

    Strength Gains: Users consistently report strength increases across all major lifts. One user noted that over 8 weeks at 10mg, strength went up "a rep or two here, 2.5lbs or 5lbs there". While not the explosive strength gains associated with compounds like RAD140, the strength increases are steady and maintainable.

    Tissue Selectivity: The compound's selectivity means minimal prostate stimulation, reduced risk of androgenic hair loss, and no conversion to DHT. For users concerned about hair retention, LGD4033 has one of the lowest androgenic profiles among the commonly used SARMs.

    No Aromatization: LGD4033 does not aromatize to estrogen, meaning no estrogen-related water retention and no risk of gynecomastia at the receptor level. This eliminates the need for aromatase inhibitors during a cycle.

    Convenience: Once-daily oral dosing with 90 percent bioavailability makes LGD4033 one of the most user-friendly anabolic compounds available.

    The dosing of LGD4033 follows a clear ladder based on experience level. The typical dosage range in the bodybuilding community is 5 to 10mg per day. Clinical trials used far lower doses-0.1 to 1mg per day-but these were designed for therapeutic applications in elderly or diseased populations, not for supraphysiological muscle growth in healthy trained individuals.

    Beginner (First Cycle): 5mg per day. This is the most commonly recommended starting point. Starting at the lower end allows the user to assess tolerance and sensitivity before potentially increasing the dose. Even at 5mg, users report significant gains, and the suppression profile is more manageable.

    Intermediate: 7.5 to 10mg per day. After a successful first cycle at 5mg, many users increase to 10mg. This is the dose most commonly reported in user logs and is generally considered the sweet spot for maximizing gains while keeping side effects within acceptable limits.

    Advanced: 10 to 20mg per day. Some experienced users push to 15 or even 20mg, but doses above 10mg are not recommended due to diminishing returns and a significantly increased risk of side effects. The clinical data shows dose-proportional accumulation, meaning higher doses produce proportionally higher suppression without necessarily producing proportionally greater muscle growth.

    The compound should be taken once daily, at roughly the same time each day, to maintain steady plasma levels. Many users prefer taking it in the morning, though pre-workout dosing is also common. Given the 24-to-36-hour half-life, timing within the day is less critical than consistency.

    Standard LGD4033 cycles run from 6 to 8 weeks. Some users extend to 10 or even 12 weeks, but this is not recommended. The compound's suppression of endogenous testosterone becomes more pronounced with longer cycles, and the marginal gains beyond week 8 tend to diminish while the side effects accumulate.

    6-Week Cycle: The minimum effective cycle length for most users. Gains are noticeable but more modest than an 8-week run. This shorter cycle may be appropriate for first-time users who want to test their response with less suppression risk.

    8-Week Cycle: The standard and most commonly recommended length. This allows sufficient time for the compound to exert its full anabolic effects while keeping suppression within a range that is recoverable with proper PCT.

    10-Week Cycle: Some experienced users extend to 10 weeks, but this increases suppression risk significantly. One user who ran a 12-week cycle noted that gains largely plateaued after week 10.

    Throughout the cycle, users should be taking supportive supplements. Liver support-specifically N-acetylcysteine (NAC) or TUDCA-is strongly recommended. Fish oil is also important, as LGD4033 has been documented to reduce HDL cholesterol in a dose-dependent manner. A comprehensive multivitamin and joint support supplement are also prudent additions.

    Bloodwork should be obtained before the cycle, at mid-cycle, at the end of the cycle, and again 4 to 6 weeks post-PCT. Key markers to monitor include total and free testosterone, LH, FSH, SHBG, liver enzymes (ALT, AST), and a full lipid panel including HDL and LDL cholesterol.

    The 24-to-36-hour elimination half-life of LGD4033 is one of its defining pharmacokinetic features. This extended half-life supports once-daily dosing, as the compound maintains therapeutic plasma levels throughout the day. However, the half-life also has implications for both the cycle and the post-cycle period.

    Because LGD4033 has a linear pharmacokinetic profile and exhibits dose-proportional accumulation, daily administration leads to steady accumulation of the compound in the blood. This means that plasma levels reach a steady state after approximately 5 half-lives-roughly 5 to 7 days. From that point forward, the compound's concentration in the blood remains relatively stable, providing consistent androgen receptor activation.

    The extended half-life also means that the compound lingers in the system after the last dose. Appreciable plasma levels can be detected a full week after discontinuation. This has practical implications for the timing of post-cycle therapy: because the compound is still present in the system, starting PCT too early may be less effective, as the suppressive effects of LGD4033 are still active. However, compared to RAD140's 44-hour half-life, LGD4033's shorter elimination window means PCT can begin sooner.

    Post-cycle therapy is not optional with LGD4033-it is a necessity. The compound causes dose-dependent suppression of endogenous testosterone production, and this suppression can be significant. Even at clinical doses of 0.1 to 1mg per day, testosterone suppression was observed. At the bodybuilding doses of 5 to 10mg per day, suppression is substantial and requires active intervention to restore natural production.

    The standard PCT protocol involves a selective estrogen receptor modulator (SERM) to stimulate the hypothalamic-pituitary-gonadal axis and restore endogenous testosterone production. The two most commonly used SERMs are enclomiphene and nolvadex.

    Enclomiphene Protocol: 12.5 to 25mg per day for 4 to 6 weeks, starting 2 to 3 days after the last LGD4033 dose. Enclomiphene is increasingly favored over older SERMs because it has no estrogenic agonist activity (unlike racemic clomiphene/Clomid) and is generally better tolerated.

    Nolvadex Protocol: A tapering protocol of 20mg per day for two weeks, then 10mg per day for two weeks-often written as 20/20/10/10. Nolvadex is a well-established PCT option with decades of use in the bodybuilding community.

    Mini-PCT: Some users run enclomiphene at a low dose (6.25 to 12.5mg per day) throughout the cycle to mitigate suppression from the start. This on-cycle SERM use is increasingly common, though less studied than traditional post-cycle protocols.

    The clinical data offers some reassurance: in the 2013 Phase 1 trial, all hormone levels returned to baseline by day 56 after discontinuation. However, this was at clinical doses far below what bodybuilders use. At 5 to 10mg per day, recovery may take longer and may require more aggressive PCT.

    PCT should begin immediately after the cycle ends-typically 24 hours after the last dose, though some protocols recommend waiting 2 to 3 days to account for the lingering compound in the system. The PCT period typically lasts 30 days. During this time, users should continue supportive supplements, maintain training intensity, and most importantly, get follow-up bloodwork to confirm that natural testosterone production has been restored.

Brand	STROMUSC
Trade names	LGD4033,Ligandrol,VK5211
CAS	1165910-22-4
Molar mass	338.253
MF	C14H12F6N2O
Purity	Above 98%
Apprarance	10mg*100

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                  

 

    LGD4033 is a powerful compound. It delivers real, visible, and measurable results-lean mass gains of 4 to 8 pounds in an 8-week cycle are achievable and well-documented. The compound's tissue selectivity, high oral bioavailability, and convenient once-daily dosing make it one of the most user-friendly anabolic agents available.

    But the trade-offs are real. Testosterone suppression is significant and requires a properly planned PCT. HDL cholesterol drops in a dose-dependent manner, necessitating cardiovascular support and lipid monitoring. Liver enzyme elevations have been documented. The compound is unregulated, and product quality varies dramatically between sources.

    Bloodwork before, during, and after a cycle is not optional-it is the only way to know what the compound is actually doing to your body. And perhaps most importantly, LGD4033 is not approved for human use. Its use in bodybuilding exists in a legal and medical gray area, and the long-term effects remain unknown.

    For those who choose to use it, the responsibility rests entirely on the individual to research thoroughly, dose responsibly, support their body with proper nutrition and supplements, and execute a proper PCT. LGD4033 can deliver remarkable results-but only when used with the respect and caution that a compound of this potency demands.

Hot Tags: high-quality stromusc lgd4033 10mg for bodybuilding cas:1165910-22-4, China high-quality stromusc lgd4033 10mg for bodybuilding cas:1165910-22-4 manufacturers, suppliers, factory, Andarine S4, Andarine S4 Build muscle, GW501516, OTR AC Gain muscle mass, RAD140 increase lean muscle mass, RAD150